[Docetaxel in the treatment of metastatic carcinoma of the salivary glands: report of a case].
We report a case history of a patient treated with single agent docetaxel (100 mg/mq every three weeks) for a metastatic salivary gland carcinoma. After surgical treatment of primary tumor, this patient underwent two subsequent resections for local relapses. However, lung and liver metastases developed which were unsuccessfully treated with carboplatin + doxorubicin, and bleomycin. Salvage therapy with docetaxel induced a significant regression (> 50%) of both liver and lung metastases. Docetaxel seems to be active in metastatic salivary gland carcinoma, and a multicentric phase II trial is now ongoing to better evaluate its activity in this disease.
Belli
F
F
Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma, Italia.
Di Lauro
L
L
Zappanico
A
A
Giunta
S
S
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy / Q000556:secondary*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009062:Mouth Neoplasms / Q000473:pathology / Q000601:surgery*; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012468:Salivary Gland Neoplasms / Q000188:drug therapy / Q000556:secondary*; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel
Docetaxel nel trattamento del carcinoma metastatico delle ghiandole salivari: presentazione di un caso clinico.